Overview

Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects

Status:
Completed
Trial end date:
2018-01-18
Target enrollment:
Participant gender:
Summary
This is a single or up to 2 centers, double-blind, randomized, single-dose, two-way, crossover study comparing the Test (T) and Reference (R) products following subcutaneous administration. Subjects will be randomly assigned to one of two treatments sequences (TR or RT). All subjects will be dosed at the CRO's designated clinical site(s) and the same protocol requirements and procedures will be followed within each group.
Phase:
Phase 1
Details
Lead Sponsor:
Adello Biologics, LLC
Collaborator:
inVentiv Health Clinical